Evaluating the immune response to combination vaccines.

Area of Science:

• Vaccinology
• Immunology
• Clinical Trials

Background:

• Assessing combination vaccine immunogenicity in the US typically uses randomized controlled trials.
• Study designs must carefully select immunologic endpoints and control groups.

Purpose of the Study:

• To outline best practices for designing clinical studies of immune responses to combination vaccines.
• To discuss the role of immunogenicity studies in combination vaccine licensure.

Main Methods:

• Reviewing principles for selecting immunologic endpoints and control groups.
• Considering simultaneous vaccine administration and schedule variations.
• Bridging international immunogenicity data to the US population.

Main Results:

• Highlights the importance of predefining acceptable immune response differences.
• Emphasizes the need for robust statistical plans.
• Discusses using immunogenicity data when field efficacy studies are not feasible.

Conclusions:

• Effective combination vaccine assessment relies on well-defined immunologic endpoints and statistical power.
• Immunogenicity studies are crucial for supporting licensure, especially for vaccines like Haemophilus influenzae type b conjugates.